Increase of NT-ProBNP levels (or BNP if NT-ProBNP not available) during follow-up is associated with worse prognosis. Measurement of the NT-ProBNP is recommended for initial risk stratification and it can be considered for monitoring the effect of treatment. However decision making should not be done on NT-ProBNP alone. It should be emphasized that NT-ProBNP is elevated in both right or left heart failure and therefore is not specific for PH worsening.
- Other markers
Uric acid and Troponin, as well as other biomarkers need further investigation in patients with PAH and are not recommended for routine clinical practice.
a depending on age
b TAPSE and pericardial effusion have been selected because they can be measured in the majority of the patients
|BNP||brain natriuretic peptide|
|6MWT||6-minute walking test|
|RAP||right atrial pressure|
|TAPSE||tricuspid annular plance systolic excursion|
|WHO-FC||WHO functional class|